Nasdaq · CIK 0000914475 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
NEUROCRINE BIOSCIENCES INC
NBIX chart by TradingView
PRICE HISTORY
LIVE · NASDAQNBIX chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $2.9B
- EBITDA
- $0.6B
- FREE CASH FLOW
- $0.7B
- EPS
- $4.67
- GROSS MARGIN
- 98.18%
- ROIC
- —
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
24.9x
-98%20.4x1198.9x
⤢
P / SALES (TTM)
5.2x
-98%4.4x223.7x
⤢
P / BOOK
4.8x
-55%4.0x26.6x
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
—
⤢
FCF YIELD (TTM)
4.96%
+8.2pp-3.29%6.10%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$1.0B
+$1.0B⤢
EBITDA (DERIVED)
$0.2B
+$0.2B⤢
NET INCOME
$0.1B
+$0.2B⤢
EPS (DILUTED)
$1.39
+$1.90⤢
REVENUE GROWTH YOY
39.49%
+139.5pp-100.00%1429.68%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
13.41%
+781.1pp-767.73%48.52%
⤢
RETURN ON CAPITAL
—
⤢
RETURN ON EQUITY (TTM)
19.10%
+54.9pp-80.99%36.17%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN—
OPERATING MARGIN15.80%
NET MARGIN15.06%
FCF MARGIN13.41%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.1B
+$0.2B⤢
STOCK-BASED COMP
$0.1B
+929%⤢
CAPITAL EXPENDITURE
$0.0B
+904%⤢
SHARES OUTSTANDING
0.10B
+20%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.3B
+233%⤢
TOTAL DEBT
—
⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 104.14%INSIDERS 1.06%OTHER / RETAIL 0.00%1,089 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 13.17% | 13.4M | $2.19B | +4.3% |
| Dodge & Cox Inc. | 5.37% | 5.5M | $892.4M | -0.9% |
| JPMORGAN CHASE & CO | 5.35% | 5.4M | $889.3M | +4.7% |
| AQR Capital Management, LLC | 4.86% | 4.9M | $807.1M | +51.0% |
| Vanguard Portfolio Management LLC | 4.65% | 4.7M | $772.3M | NEW |
| Vanguard Capital Management LLC | 4.44% | 4.5M | $737.3M | NEW |
| State Street Corporation | 4.28% | 4.4M | $711.6M | +2.6% |
| Two Sigma Investments, LP | 3.01% | 3.1M | $500.1M | +210.8% |
| Renaissance Technologies, LLC | 2.38% | 2.4M | $395.3M | +8.0% |
| Geode Capital Management, LLC | 2.10% | 2.1M | $349.2M | +3.8% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.